Stay updated on Tabelecleucel & Pembrolizumab in EBV+ NPC Clinical Trial
Sign up to get notified when there's something new on the Tabelecleucel & Pembrolizumab in EBV+ NPC Clinical Trial page.

Latest updates to the Tabelecleucel & Pembrolizumab in EBV+ NPC Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe clinical trial record for tabelecleucel plus pembrolizumab in EBV-associated nasopharyngeal carcinoma is now displayed, including its study design, eligibility, outcomes, and posted results. It reports that the study was terminated after Phase 1B and that Phase 2 was not conducted.SummaryDifference73%

- Check19 days agoChange DetectedThe footer now identifies the site as revision v3.8.0 instead of v3.7.2, while the page continues to display a 403 error.SummaryDifference0.2%

- Check26 days agoChange DetectedA site-wide notice announces a terminology change from “Artificial Intelligence” to “Super Intelligence” and links to transition updates and FAQs. The study page still displays a 403 error.SummaryDifference1%

- Check33 days agoChange DetectedThe site footer revision changed from v3.7.1 to v3.7.2 on the 403 error page.SummaryDifference0.2%

- Check40 days agoChange DetectedThe footer revision identifier changed from v3.7.0 to v3.7.1, while the study record remains unavailable behind a 403 error.SummaryDifference0.2%

- Check61 days agoChange DetectedThe page now displays a 403 Forbidden error page, with a 403 title and Forbidden message shown in the HTML, indicating access restrictions rather than study content. The site layout remains visible, but substantive content is not accessible.SummaryDifference21%

Stay in the know with updates to Tabelecleucel & Pembrolizumab in EBV+ NPC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tabelecleucel & Pembrolizumab in EBV+ NPC Clinical Trial page.